Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation and Depletion (2016 - 2020)

Historic Depreciation and Depletion for Ani Pharmaceuticals (ANIP) over the last 9 years, with Q4 2020 value amounting to $1.3 million.

  • Ani Pharmaceuticals' Depreciation and Depletion rose 833.33% to $1.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.9 million, marking a year-over-year increase of 652.17%. This contributed to the annual value of $7.4 million for FY2024, which is 133.33% down from last year.
  • According to the latest figures from Q4 2020, Ani Pharmaceuticals' Depreciation and Depletion is $1.3 million, which was up 833.33% from $1.2 million recorded in Q3 2020.
  • Ani Pharmaceuticals' 5-year Depreciation and Depletion high stood at $1.3 million for Q4 2020, and its period low was $200000.0 during Q1 2016.
  • Over the past 5 years, Ani Pharmaceuticals' median Depreciation and Depletion value was $500000.0 (recorded in 2018), while the average stood at $680000.0.
  • In the last 5 years, Ani Pharmaceuticals' Depreciation and Depletion changed by 0.0% in 2016 and then soared by 30000.0% in 2019.
  • Over the past 5 years, Ani Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $200000.0 in 2016, then surged by 50.0% to $300000.0 in 2017, then surged by 166.67% to $800000.0 in 2018, then surged by 50.0% to $1.2 million in 2019, then rose by 8.33% to $1.3 million in 2020.
  • Its Depreciation and Depletion was $1.3 million in Q4 2020, compared to $1.2 million in Q3 2020 and $1.2 million in Q2 2020.